Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response-Reference-Cited by-同舟云学术

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response

Published:2013-09-15 Issue:5 Volume:7 Page:611-615
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut Liver

Author:

Park Semi,Chung Moon Jae,Park Jeong Youp,Chung Jae Bock,Bang Seungmin,Park Seung Woo,Song Si Young

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2013/007/gnl-7-611.pdf

Reference18 articles.

1. Systemic treatment of pancreatic cancer

2. Epidemiology and Prevention of Pancreatic Cancer

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

4. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

5. Phase II study of gemcitabine in patients with advanced pancreatic cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis and systematic review of randomized controlled trials in combination Gemcitabine with Erlotinib in the pancreatic cancer;2023-11-11

2. Therapy targeting angiogenic potential of tumor;Nanotechnology Applications for Cancer Chemotherapy;2021

3. Erlotinib plus Gemcitabin als Therapie bei Patienten mit metastasiertem Pankreaskarzinom: Ergebnisse einer nicht-interventionellen Studie;Zeitschrift für Gastroenterologie;2020-02-12

4. 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling;Cancer Letters;2020-02

5. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis;OncoTargets and Therapy;2018-10